Key Details
Annual ROE
-57.57%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 10, 2023Recent annual earnings:
Mar 10, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 30, 2022Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with GMTX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Gemini Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Gemini Therapeutics?
- What is the ticker symbol for Gemini Therapeutics?
- Does Gemini Therapeutics pay dividends?
- What sector is Gemini Therapeutics in?
- What industry is Gemini Therapeutics in?
- What country is Gemini Therapeutics based in?
- When did Gemini Therapeutics go public?
- Is Gemini Therapeutics in the S&P 500?
- Is Gemini Therapeutics in the NASDAQ 100?
- Is Gemini Therapeutics in the Dow Jones?
- When was Gemini Therapeutics's last earnings report?
- When does Gemini Therapeutics report earnings?
What is the primary business of Gemini Therapeutics?
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
What is the ticker symbol for Gemini Therapeutics?
The ticker symbol for Gemini Therapeutics is NASDAQ:GMTX
Does Gemini Therapeutics pay dividends?
No, Gemini Therapeutics does not pay dividends
What sector is Gemini Therapeutics in?
Gemini Therapeutics is in the Healthcare sector
What industry is Gemini Therapeutics in?
Gemini Therapeutics is in the Biotechnology industry
What country is Gemini Therapeutics based in?
Gemini Therapeutics is headquartered in United States
When did Gemini Therapeutics go public?
Gemini Therapeutics's initial public offering (IPO) was on 12 August 2020
Is Gemini Therapeutics in the S&P 500?
No, Gemini Therapeutics is not included in the S&P 500 index
Is Gemini Therapeutics in the NASDAQ 100?
No, Gemini Therapeutics is not included in the NASDAQ 100 index
Is Gemini Therapeutics in the Dow Jones?
No, Gemini Therapeutics is not included in the Dow Jones index
When was Gemini Therapeutics's last earnings report?
Gemini Therapeutics's most recent earnings report was on 10 March 2023
When does Gemini Therapeutics report earnings?
The date for Gemini Therapeutics's next earnings report has not been announced yet